Blau Farmacêutica Publishes 3Q26 Earnings Call Transcript

PUBT · 1d ago
Blau Farmacêutica Publishes 3Q26 Earnings Call Transcript
  • Blau Farmacêutica held its 3Q26 earnings call with CEO Marcelo Hahn, CFO Douglas Rodrigues and investor relations representative Matheus Fujisawa.
  • Quarterly revenue rose 7% to R$ 506 million; recurring EBITDA margin increased 120 basis points to 25.3%.
  • Pembrolizumab's multinational clinical study is starting, with completion targeted for late 2027; launch is expected in approximately two years.
  • Two newly operational production lines could contribute 4%-5% of revenue; two more await authorization, targeted for the first half of 2027.
  • Capital spending should exceed 2026 levels but remain within EBITDA generated in 2027; the main Pernambuco project is progressing more slowly.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.